Skip to content
SlushFund

Companies · USAspending parent record

TEVA PHARMACEUTICALS USA, INC.

No confirmed stock ticker. 1 recipient record grouped under this USAspending parent (UEI NEN9A34LRHJ5).

Non-competed awards
$40.9M

obligated to date on 21 non-competed awards of $1M+ signed FY2024–26

USAspendingas of Oct 3

Obligated to date, not spending in a year. Selected awards only (rule r5-v1): not this company's not-competed share.

Awards in our records
21

21 non-competed ($1M+) · 0 other ($10M+)

USAspendingas of Oct 3
Largest award
$5.3M

obligated to date: SPE2DP25F2789, Department of Defense, signed FY2025

USAspendingas of Oct 3
Member trades
No ticker

No confirmed stock ticker, so no member trades are matched to this company.

House Clerk + Senate eFDas of Oct 4
Source: USAspending.gov · SEC EDGAR company tickers · House Clerk PTRs · Senate eFDCoverage: Contract awards FY2024–FY2026 · Ticker links FY2024–26 recipients · House 2021–2026 · Senate 2024–2026Updated: Methodology →

Federal contract awards in our records

Each row is one prime contract award on USAspending.gov; “USAspending” opens its official page.

What this table covers: every award signed in FY2024–26 that the agency coded “not competed” and that is $1 million or more, plus any award of $10 million or more (rule r5-v1). Smaller competed awards are not in it, so it is not this company’s total federal business and it cannot show a not-competed share. “Obligated to date” is the total committed on the award so far, including later modifications (USAspending, as of Oct 3, 2026), not the amount at any earlier date.

Awards by fiscal year signed (obligated to date, not spending in the year)
Signed inNon-competed awardsObligated to dateOther awards $10M+Obligated to date
FY20248$10.6MNone in this set—
FY20254$10.8MNone in this set—
FY2026incomplete9$19.4MNone in this set—

FY2026 is incomplete: the Department of Defense reports contract actions 90 days late, and older awards keep growing through modifications, so these amounts will rise. Source: USAspending.gov, as of Oct 3, 2026.

FY2024–26 awards to TEVA PHARMACEUTICALS USA, INC., largest first (obligated to date)
Source
SPE2DP25F2789Order under IDV SPE2DP20D00028511147946!ADENOVIRUS TYPE 4 ADepartment of DefenseJan 28, 2025FY2025Not competedOnly one source-other (FAR 6.302-1 other)$5,285,022USAspending
SPE2DP26F1649Order under IDV SPE2DP20D00028511856699!ADENOVIRUS TYPE 4 ADepartment of DefenseJan 13, 2026FY2026Not competedOnly one source-other (FAR 6.302-1 other)$3,950,554USAspending
SPE2DP26F2814Order under IDV SPE2DP20D00028511918533!ADENOVIRUS TYPE 4 ADepartment of DefenseFeb 17, 2026FY2026Not competedOnly one source-other (FAR 6.302-1 other)$3,950,554USAspending
SPE2DP26F3586Order under IDV SPE2DP20D00028511984334!ADENOVIRUS TYPE 4 ADepartment of DefenseMar 18, 2026FY2026Not competedOnly one source-other (FAR 6.302-1 other)$3,950,554USAspending
SPE2DP25F0856Order under IDV SPE2DP20D00028511009796!ADENOVIRUS TYPE 4 ADepartment of DefenseNov 14, 2024FY2025Not competedOnly one source-other (FAR 6.302-1 other)$3,176,095USAspending
SPE2DP26F0979Order under IDV SPE2DP20D00028511784063!ADENOVIRUS TYPE 4 ADepartment of DefenseDec 1, 2025FY2026Not competedOnly one source-other (FAR 6.302-1 other)$1,981,883USAspending
SPE2DP24F3911Order under IDV SPE2DP20D00028510559015!ADENOVIRUS TYPE 4 ADepartment of DefenseApr 9, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,588,047USAspending
SPE2DP24F4773Order under IDV SPE2DP20D00028510634433!ADENOVIRUS TYPE 4 ADepartment of DefenseMay 15, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,429,243USAspending
SPE2DP24F5483Order under IDV SPE2DP20D00028510688482!ADENOVIRUS TYPE 4 ADepartment of DefenseJun 13, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,429,243USAspending
SPE2DP24F6263Order under IDV SPE2DP20D00028510766857!ADENOVIRUS TYPE 4 ADepartment of DefenseJul 19, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,429,243USAspending
SPE2DP26F0980Order under IDV SPE2DP20D00028511784064!ADENOVIRUS TYPE 4 ADepartment of DefenseDec 1, 2025FY2026Not competedOnly one source-other (FAR 6.302-1 other)$1,321,255USAspending
SPE2DP24F1993Order under IDV SPE2DP20D00028510401601!ADENOVIRUS TYPE 4 ADepartment of DefenseJan 25, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,270,438USAspending
SPE2DP24F7996Order under IDV SPE2DP20D00028510902080!ADENOVIRUS TYPE 4 ADepartment of DefenseSep 18, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,270,438USAspending
SPE2DP26F6513Order under IDV SPE2DP20D00028512183379!ADENOVIRUS TYPE 4 ADepartment of DefenseJun 16, 2026FY2026Not competedOnly one source-other (FAR 6.302-1 other)$1,202,342USAspending
SPE2DP25F055DOrder under IDV SPE2DP20D00028511565495!ADENOVIRUS TYPE 4 ADepartment of DefenseAug 12, 2025FY2025Not competedOnly one source-other (FAR 6.302-1 other)$1,156,099USAspending
SPE2DP25F2792Order under IDV SPE2DP20D00028511148052!ADENOVIRUS TYPE 4 ADepartment of DefenseJan 28, 2025FY2025Not competedOnly one source-other (FAR 6.302-1 other)$1,156,099USAspending
SPE2DP24F3172Order under IDV SPE2DP20D00028510500489!ADENOVIRUS TYPE 4 ADepartment of DefenseMar 13, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,111,633USAspending
SPE2DP24F7165Order under IDV SPE2DP20D00028510839749!ADENOVIRUS TYPE 4 ADepartment of DefenseAug 22, 2024FY2024Not competedOnly one source-other (FAR 6.302-1 other)$1,111,633USAspending
SPE2DP26F4633Order under IDV SPE2DP20D00028512041924!ADENOVIRUS TYPE 4 ADepartment of DefenseApr 15, 2026FY2026Not competedOnly one source-other (FAR 6.302-1 other)$1,030,579USAspending
SPE2DP26F5466Order under IDV SPE2DP20D00028512097239!ADENOVIRUS TYPE 4 ADepartment of DefenseMay 11, 2026FY2026Not competedOnly one source-other (FAR 6.302-1 other)$1,030,579USAspending
SPE2DP26F6514Order under IDV SPE2DP20D00028512183483!ADENOVIRUS TYPE 4 ADepartment of DefenseJun 16, 2026FY2026Not competedOnly one source-other (FAR 6.302-1 other)$1,030,579USAspending

FY2024–26 awards to TEVA PHARMACEUTICALS USA, INC., largest first (obligated to date)

  • SPE2DP25F2789Order under IDV SPE2DP20D00028511147946!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jan 28, 2025FY2025
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $5,285,022
    USAspending
  • SPE2DP26F1649Order under IDV SPE2DP20D00028511856699!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jan 13, 2026FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $3,950,554
    USAspending
  • SPE2DP26F2814Order under IDV SPE2DP20D00028511918533!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Feb 17, 2026FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $3,950,554
    USAspending
  • SPE2DP26F3586Order under IDV SPE2DP20D00028511984334!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Mar 18, 2026FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $3,950,554
    USAspending
  • SPE2DP25F0856Order under IDV SPE2DP20D00028511009796!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Nov 14, 2024FY2025
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $3,176,095
    USAspending
  • SPE2DP26F0979Order under IDV SPE2DP20D00028511784063!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Dec 1, 2025FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,981,883
    USAspending
  • SPE2DP24F3911Order under IDV SPE2DP20D00028510559015!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Apr 9, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,588,047
    USAspending
  • SPE2DP24F4773Order under IDV SPE2DP20D00028510634433!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    May 15, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,429,243
    USAspending
  • SPE2DP24F5483Order under IDV SPE2DP20D00028510688482!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jun 13, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,429,243
    USAspending
  • SPE2DP24F6263Order under IDV SPE2DP20D00028510766857!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jul 19, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,429,243
    USAspending
  • SPE2DP26F0980Order under IDV SPE2DP20D00028511784064!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Dec 1, 2025FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,321,255
    USAspending
  • SPE2DP24F1993Order under IDV SPE2DP20D00028510401601!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jan 25, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,270,438
    USAspending
  • SPE2DP24F7996Order under IDV SPE2DP20D00028510902080!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Sep 18, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,270,438
    USAspending
  • SPE2DP26F6513Order under IDV SPE2DP20D00028512183379!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jun 16, 2026FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,202,342
    USAspending
  • SPE2DP25F055DOrder under IDV SPE2DP20D00028511565495!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Aug 12, 2025FY2025
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,156,099
    USAspending
  • SPE2DP25F2792Order under IDV SPE2DP20D00028511148052!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jan 28, 2025FY2025
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,156,099
    USAspending
  • SPE2DP24F3172Order under IDV SPE2DP20D00028510500489!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Mar 13, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,111,633
    USAspending
  • SPE2DP24F7165Order under IDV SPE2DP20D00028510839749!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Aug 22, 2024FY2024
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,111,633
    USAspending
  • SPE2DP26F4633Order under IDV SPE2DP20D00028512041924!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Apr 15, 2026FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,030,579
    USAspending
  • SPE2DP26F5466Order under IDV SPE2DP20D00028512097239!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    May 11, 2026FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,030,579
    USAspending
  • SPE2DP26F6514Order under IDV SPE2DP20D00028512183483!ADENOVIRUS TYPE 4 A
    Agency
    Department of Defense
    Signed
    Jun 16, 2026FY2026
    Competition
    Not competedOnly one source-other (FAR 6.302-1 other)
    Obligated to date
    $1,030,579
    USAspending
21 awards. Source: USAspending.gov award records.
Recipient records grouped under this company (1)

USAspending groups recipients by its parent-company field, which has known errors. Check that the recipients below belong to TEVA PHARMACEUTICALS USA, INC.; the stock link below is made per recipient.

  • TEVA PHARMACEUTICALS USA, INC.21 awards · 21 non-competed, $40.9M obligated to date

Stock ticker

Links between a federal contract recipient and an SEC-registered company, made by a written rule from SEC filings and USAspending records. Only confirmed links are shown.

No confirmed stock ticker: this may be a private company, a subsidiary awaiting review, or not matched to an SEC registrant.

Members of Congress who reported trading this stock

No confirmed stock ticker: this may be a private company, a subsidiary awaiting review, or not matched to an SEC registrant. Without a confirmed ticker, no trades are matched to this company.

Looking for agency-level shares? See non-competed share by agency.